Cartalax (25mg)

Fibroblast Proliferation:

In cultured fibroblast models, Cartalax increases proliferation markers such as Ki‑67 and CD98hc while reducing caspase‑3–mediated apoptosis—suggesting enhanced cell survival and replicative capacity [2][3]. 

Apoptosis Regulation:

Exposure to Cartalax correlates with decreased expression of pro-apoptotic p53, indicating potential for longevity enhancement in cellular models [2]. 

Extracellular Matrix Stabilization:

Cartalax downregulates MMP‑9 in aged fibroblast cultures, potentially preserving collagen and extracellular matrix integrity [2][3]. 

Cell-Specific Gene Expression:

Research implies modulation of senescence-associated genes (p16, p21) and the longevity-associated enzyme SIRT‑6 in aging cell models [2]. 

Epigenetic and Nuclear Effects:

Preclinical data suggest Cartalax may interact with nuclear DNA or regulatory proteins, affecting transcription of matrix-related genes and stress-resilience pathways [2][3][4]. 

Citations

1. PubChem Compound Summary for Cartalax (AED peptide, CID 87815447; formula C₁₂H₁₉N₃O₈; MW 333.29 Da). 
2. Pep‑Pedia, Cartalax (AED peptide) research overview: stimulation of Ki‑67/CD98hc, reduced caspase‑3, p53 and MMP‑9 in fibroblast models. 
3. Pep‑Pedia, detailed cellular effects including gene-expression modulation (p16, p21, SIRT‑6) and epigenetic interactions. 
4. Battle Born Peptides, Cartalax in cartilage/connective tissue & inflammatory studies showing epigenetic regulation and chondrocyte preservation in osteoarthritis models.
5. PubChem Compound Summary again confirms sequence and synonyms (AED, T‑31).